Compare DUOT & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOT | ALXO |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.3M | 240.8M |
| IPO Year | 2017 | 2020 |
| Metric | DUOT | ALXO |
|---|---|---|
| Price | $13.77 | $1.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $17.00 | $3.50 |
| AVG Volume (30 Days) | 828.9K | ★ 933.6K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.96 | 26.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,023,651.00 | N/A |
| Revenue This Year | $50.98 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 271.16 | N/A |
| 52 Week Low | $5.78 | $0.41 |
| 52 Week High | $15.28 | $2.66 |
| Indicator | DUOT | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 68.08 | 41.81 |
| Support Level | $8.12 | $1.54 |
| Resistance Level | N/A | $1.90 |
| Average True Range (ATR) | 1.22 | 0.11 |
| MACD | 0.44 | -0.03 |
| Stochastic Oscillator | 80.36 | 25.61 |
Duos Technologies Group Inc delivers AI-driven technologies, edge computing infrastructure, and energy consulting services to support data-intensive and mission-critical operations. It manages, operates, engineers, software development, customer support and project implementation and management across three market segments, including rail technology deployment, Data Center co-location facilities, and behind-the-meter electrical power provision. It also continues to operate as a technology company which designs, develops, deploys, and operates intelligent technology solutions with a focus on software applications and artificial intelligence (AI) in addition to large projects, consulting, implementation, and asset management.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.